Variant Gene Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
dbSNP: rs121434592
rs121434592
0.700 GeneticVariation CLINVAR Prospective enterprise-level molecular genotyping of a cohort of cancer patients. 25157968

2015

dbSNP: rs121913430
rs121913430
0.700 GeneticVariation CLINVAR Prospective enterprise-level molecular genotyping of a cohort of cancer patients. 25157968

2015

dbSNP: rs121434592
rs121434592
0.700 GeneticVariation CLINVAR The mutational landscape of lethal castration-resistant prostate cancer. 22722839

2012

dbSNP: rs121434592
rs121434592
0.700 GeneticVariation CLINVAR Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. 22610119

2012

dbSNP: rs138213197
rs138213197
0.020 GeneticVariation BEFREE Somatic molecular subtyping of prostate tumors from HOXB13 G84E carriers. 28186998

2017

dbSNP: rs138213197
rs138213197
0.020 GeneticVariation BEFREE PSA testing, six-core biopsy, genetic counselling and mutation analysis for French Canadian founder mutations in the BRCA1 and BRCA2 genes, histopathological review of tumour tissue from family members, examination of loss of heterozygosity at the BRCA2 gene locus, immunohistochemistry to determine the expression of the ERG nuclear oncoprotein in prostate tumours, genotyping with eight selected risk-associated single nucleotide polymorphisms, Doppler ultrasonography of the leg, CT of the abdomen and pelvis with intravenous and oral contrast, chest CT with intravenous contrast for the assessment of metastatic prostate cancer, genetic testing for the G84E variant in the HOXB13 gene. 23318356

2013

dbSNP: rs137852578
rs137852578
AR
0.020 GeneticVariation BEFREE The gene expression profile of AR-E231G prostate tissue from 12-week-old mice was compared to an equivalent profile from mice expressing the AR-T857A receptor variant (analogous to the AR-T877A variant in LNCaP cells), which do not develop prostate tumors. 22275114

2012

dbSNP: rs137852578
rs137852578
AR
0.020 GeneticVariation BEFREE Human LNCaP cells, extensively used as a model for androgen-dependent prostate tumor, express the androgen receptor (AR) mutant T877A promiscuously transactivated by estrogens and other ligands, which may further facilitate cancer progression. 12391264

2002

dbSNP: rs1060501201
rs1060501201
0.010 GeneticVariation BEFREE Somatic molecular subtyping of prostate tumors from HOXB13 G84E carriers. 28186998

2017

dbSNP: rs1197734477
rs1197734477
0.010 GeneticVariation BEFREE Somatic molecular subtyping of prostate tumors from HOXB13 G84E carriers. 28186998

2017

dbSNP: rs339331
rs339331
0.010 GeneticVariation BEFREE Finally, we observe a significant association between the risk-associated T allele at rs339331 and increased RFX6 mRNA levels in human prostate tumors. 24390282

2014

dbSNP: rs375118292
rs375118292
0.010 GeneticVariation BEFREE Analysis of the prostate tumor from this individual verified the presence of heterozygous N296I as well as an ERG fusion. 24796539

2014

dbSNP: rs727502792
rs727502792
0.010 GeneticVariation BEFREE Analysis of the prostate tumor from this individual verified the presence of heterozygous N296I as well as an ERG fusion. 24796539

2014

dbSNP: rs368015309
rs368015309
0.010 GeneticVariation BEFREE PSA testing, six-core biopsy, genetic counselling and mutation analysis for French Canadian founder mutations in the BRCA1 and BRCA2 genes, histopathological review of tumour tissue from family members, examination of loss of heterozygosity at the BRCA2 gene locus, immunohistochemistry to determine the expression of the ERG nuclear oncoprotein in prostate tumours, genotyping with eight selected risk-associated single nucleotide polymorphisms, Doppler ultrasonography of the leg, CT of the abdomen and pelvis with intravenous and oral contrast, chest CT with intravenous contrast for the assessment of metastatic prostate cancer, genetic testing for the G84E variant in the HOXB13 gene. 23318356

2013

dbSNP: rs16861209
rs16861209
0.010 GeneticVariation BEFREE Two of the risk SNPs (rs266729 and rs182052) plus four other SNPs (rs16861209, rs17366568, rs3774261, and rs7639352) were also associated with plasma adiponectin levels, and three of these (rs1686109, rs17366568, and rs3774261) were also significantly associated with IR expression in prostate tumor tissue. 21960694

2012

dbSNP: rs17366568
rs17366568
0.010 GeneticVariation BEFREE Two of the risk SNPs (rs266729 and rs182052) plus four other SNPs (rs16861209, rs17366568, rs3774261, and rs7639352) were also associated with plasma adiponectin levels, and three of these (rs1686109, rs17366568, and rs3774261) were also significantly associated with IR expression in prostate tumor tissue. 21960694

2012

dbSNP: rs182052
rs182052
0.010 GeneticVariation BEFREE Two of the risk SNPs (rs266729 and rs182052) plus four other SNPs (rs16861209, rs17366568, rs3774261, and rs7639352) were also associated with plasma adiponectin levels, and three of these (rs1686109, rs17366568, and rs3774261) were also significantly associated with IR expression in prostate tumor tissue. 21960694

2012

dbSNP: rs266729
rs266729
0.010 GeneticVariation BEFREE Two of the risk SNPs (rs266729 and rs182052) plus four other SNPs (rs16861209, rs17366568, rs3774261, and rs7639352) were also associated with plasma adiponectin levels, and three of these (rs1686109, rs17366568, and rs3774261) were also significantly associated with IR expression in prostate tumor tissue. 21960694

2012

dbSNP: rs3774261
rs3774261
0.010 GeneticVariation BEFREE Two of the risk SNPs (rs266729 and rs182052) plus four other SNPs (rs16861209, rs17366568, rs3774261, and rs7639352) were also associated with plasma adiponectin levels, and three of these (rs1686109, rs17366568, and rs3774261) were also significantly associated with IR expression in prostate tumor tissue. 21960694

2012

dbSNP: rs7639352
rs7639352
0.010 GeneticVariation BEFREE Two of the risk SNPs (rs266729 and rs182052) plus four other SNPs (rs16861209, rs17366568, rs3774261, and rs7639352) were also associated with plasma adiponectin levels, and three of these (rs1686109, rs17366568, and rs3774261) were also significantly associated with IR expression in prostate tumor tissue. 21960694

2012

dbSNP: rs486907
rs486907
0.010 GeneticVariation BEFREE A novel gammaretrovirus named xenotropic murine leukemia virus-related virus (XMRV) has been recently identified and found to have a prevalence of 40% in prostate tumor samples from American patients carrying a homozygous R462Q mutation in the RNaseL gene. 19835577

2010

dbSNP: rs113488022
rs113488022
0.010 GeneticVariation BEFREE Importantly, genetic extinction of BRAF(V600E) in established prostate tumors did not lead to tumor regression, indicating that while sufficient to initiate development of invasive prostate adenocarcinoma, BRAF(V600E) is not required for its maintenance. 19079609

2009

dbSNP: rs1571801
rs1571801
0.010 GeneticVariation BEFREE Analysis of the distribution of these SNPs among 1032 prostate cancer patients and 571 control subjects of European descent indicated that one, rs1571801, located in the DAB2IP gene, which encodes a novel Ras GTPase-activating protein and putative prostate tumor suppressor, was associated with aggressive prostate cancer (one-sided P value = .004). 18073375

2007

dbSNP: rs140191758
rs140191758
0.010 GeneticVariation BEFREE The two truncating variants (Ser(32)Stop and Arg(21)insG) were found in 3% (4 of 132) of unselected prostate tumor samples. 17079449

2006

dbSNP: rs28909982
rs28909982
0.010 GeneticVariation BEFREE In this study, we have identified two novel somatic CHEK2 mutations, c.349A > G (p.R117G) and c.967A > C (p.E321K), in prostate tumor specimens and investigated the functions of these mutants in vivo. 16835864

2006